PTHS
Pelthos Therapeutics Inc.
Biotechnology
Market Cap$15M
5Y Perf.+105.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PTHS vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
MCK
McKesson Corporation
Medical - Distribution
Market Cap$92.15B
5Y Perf.+2.7%
PTHS vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PTHS | MCK |
|---|---|---|
| Industry | Biotechnology | Medical - Distribution |
| Market Cap | $15M | $92.15B |
| Revenue (TTM) | $7M | $403.43B |
| Net Income (TTM) | $-24M | $4.76B |
| Gross Margin | 54.3% | 3.6% |
| Operating Margin | -300.5% | 1.5% |
| Forward P/E | — | 19.3x |
| Total Debt | $2M | $7.39B |
| Cash & Equiv. | $513K | $5.69B |
PTHS vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PTHS
MCK
| Stock | Jun 25 | May 26 | Return |
|---|---|---|---|
| Pelthos Therapeutic… (PTHS) | 100 | 205.6 | +105.6% |
| McKesson Corporation (MCK) | 100 | 102.7 | +2.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PTHS vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MCK leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Pelthos Therapeutics Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PTHS
Pelthos Therapeutics Inc.
The Momentum Pick
PTHS is the clearest fit if your priority is momentum.
- +119.6% vs MCK's +4.6%
Best for: momentum
MCK
McKesson Corporation
The Income Pick
MCK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 17 yrs, beta 0.04, yield 0.4%
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs PTHS's 119.6%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MCK | 16.2% revenue growth vs PTHS's -114.7% |
| Quality / Margins | MCK | 1.2% margin vs PTHS's -318.4% |
| Stability / Safety | MCK | Beta 0.04 vs PTHS's 0.68 |
| Dividends | MCK | 0.4% yield; 17-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | PTHS | +119.6% vs MCK's +4.6% |
| Efficiency (ROA) | MCK | 5.7% ROA vs PTHS's -18.7% |
PTHS vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
PTHS vs MCK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMCKLAGGINGPTHS
PTHSPelthos Therapeutics …
1leads
MCKMcKesson Corporation
3leads
6 Total Categories
CATEGORYLEADERvs PTHSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MCK4/5
Valuation MetricsMultiples, price ratios, and targets
PTHS1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MCK4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
MCK2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MCK leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $403.4B annually — 54473.4x PTHS's $7M. Profitability is closely matched — net margins range from 1.2% (MCK) to -3.2% (PTHS).
| Metric | PTHSPelthos Therapeut… | MCKMcKesson Corporat… |
|---|---|---|
| RevenueTrailing 12 months | $7M | $403.4B |
| EBITDAEarnings before interest/tax | -$21M | $6.8B |
| Net IncomeAfter-tax profit | -$24M | $4.8B |
| Free Cash FlowCash after capex | -$17M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +54.3% | +3.6% |
| Operating MarginEBIT ÷ Revenue | -3.0% | +1.5% |
| Net MarginNet income ÷ Revenue | -3.2% | +1.2% |
| FCF MarginFCF ÷ Revenue | -2.3% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -7.7% | +37.0% |
MCK leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
PTHS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | PTHSPelthos Therapeut… | MCKMcKesson Corporat… |
|---|---|---|
| Market CapShares × price | $15M | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $17M | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.91x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.28x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.75x |
| EV / EBITDAEnterprise value multiple | — | 18.74x |
| Price / SalesMarket cap ÷ Revenue | — | 0.26x |
| Price / BookPrice ÷ Book value/share | — | — |
| Price / FCFMarket cap ÷ FCF | — | 17.63x |
PTHS leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
MCK leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-40 for PTHS. On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs PTHS's 4/9, reflecting solid financial health.
| Metric | PTHSPelthos Therapeut… | MCKMcKesson Corporat… |
|---|---|---|
| ROE (TTM)Return on equity | -40.5% | +3.0% |
| ROA (TTM)Return on assets | -18.7% | +5.7% |
| ROICReturn on invested capital | — | +5.4% |
| ROCEReturn on capital employed | — | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $2M | $1.7B |
| Cash & Equiv.Liquid assets | $513,443 | $5.7B |
| Total DebtShort + long-term debt | $2M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | -12.31x | 33.79x |
MCK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — PTHS and MCK each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $21,958 for PTHS. Over the past 12 months, PTHS leads with a +119.6% total return vs MCK's +4.6%. The 3-year compound annual growth rate (CAGR) favors PTHS at 30.0% vs MCK's 27.3% — a key indicator of consistent wealth creation.
| Metric | PTHSPelthos Therapeut… | MCKMcKesson Corporat… |
|---|---|---|
| YTD ReturnYear-to-date | -12.0% | -8.5% |
| 1-Year ReturnPast 12 months | +119.6% | +4.6% |
| 3-Year ReturnCumulative with dividends | +119.6% | +106.4% |
| 5-Year ReturnCumulative with dividends | +119.6% | +286.9% |
| 10-Year ReturnCumulative with dividends | +119.6% | +348.1% |
| CAGR (3Y)Annualised 3-year return | +30.0% | +27.3% |
Evenly matched — PTHS and MCK each lead in 3 of 6 comparable metrics.
Risk & Volatility
MCK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than PTHS's 0.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCK currently trades 75.3% from its 52-week high vs PTHS's 47.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PTHSPelthos Therapeut… | MCKMcKesson Corporat… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 0.04x |
| 52-Week HighHighest price in past year | $54.29 | $999.00 |
| 52-Week LowLowest price in past year | $11.20 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +47.7% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 58.7 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 11K | 757K |
MCK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
MCK is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | PTHSPelthos Therapeut… | MCKMcKesson Corporat… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $1006.50 |
| # AnalystsCovering analysts | — | 31 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 17 |
| Dividend / ShareAnnual DPS | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.1% | +3.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
MCK leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PTHS leads in 1 (Valuation Metrics). 1 tied.
Best OverallMcKesson Corporation (MCK)Leads 3 of 6 categories
Loading custom metrics...
PTHS vs MCK: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PTHS or MCK a better buy right now?
McKesson Corporation (MCK) offers the better valuation at 29.
2x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PTHS or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to +119. 6% for Pelthos Therapeutics Inc. (PTHS). Over 10 years, the gap is even starker: MCK returned +348. 1% versus PTHS's +119. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PTHS or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus Pelthos Therapeutics Inc. 's 0. 68β — meaning PTHS is approximately 1479% more volatile than MCK relative to the S&P 500.
04Which is growing faster — PTHS or MCK?
On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14.
9% year-over-year, compared to -5. 8% for Pelthos Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PTHS or MCK?
McKesson Corporation (MCK) is the more profitable company, earning 0.
9% net margin versus -318. 4% for Pelthos Therapeutics Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus -300. 5% for PTHS. At the gross margin level — before operating expenses — PTHS leads at 54. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PTHS or MCK?
In this comparison, MCK (0.
4% yield) pays a dividend. PTHS does not pay a meaningful dividend and should not be held primarily for income.
07Is PTHS or MCK better for a retirement portfolio?
For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, PTHS: +119. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PTHS and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PTHS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.